

19 January 2024

CVS Group Plc

("CVS" or the "Company")

Exercise of SAYE Options and PDMR Dealing

CVS, one of the UK's leading providers of integrated veterinary services, announces that on 19 January 2024, options over a total of 6,126 ordinary shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group 2020 SAYE Plan (2020/2024), at an exercise price of £10.09.

The issuance of shares in connection with the SAYE Exercise was fully satisfied by 6,126 Ordinary Shares held by the CVS Group Employee Benefit Trust (the "EBT"). Following the SAYE Exercise, a total of 645 Ordinary Shares are held by the EBT, representing approximately 0.001% of the Company's total voting rights.

Ben Jacklin, Deputy CEO exercised options over 570 Ordinary Shares in the Company. The balance of the options were exercised by certain other employees and former employees of the Company.

Following his option exercise, Ben Jacklin, along with any persons closely associated, holds a beneficial interest in 37,284 Ordinary Shares in the Company, representing approximately 0.052% of the total voting rights of the Company, calculated on the same basis.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Contacts:

CVS Group plc via Camarco
Richard Fairman, CEO
Scott Morrison, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR) +44 (0)7733 124 226
Geoffrey Pelham-Lane
Ginny Pulbrook +44 (0)7961 315 138

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Ben Jacklin
2	Reason for the notification	
a)	Position/status	Deputy CEO
b)	Initial notification /Amendment	Initial Notification
3	Details of the transaction	

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	CVS Group plc
b)	LEI	213800J41XDQ2NX48O05
4	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2 pence each GB00B2863827	
b)	Nature of the transaction	Exercise of options under the 2020 SAYE Plan (1 January 2024 maturity)	
c)	Price(s) and volume(s)	Price(s)	Volume
		£10.09	570
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction	
e)	Date of the transaction	19 January 2024	
f)	Place of the transaction	Outside a trading Venue	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHZKLFFZFLBBL